
Articles of note for people dealing with pituitary disease and related conditions.

The latest from pharmaceutical companies and healthcare organizations

Brief, insightful commentary from Dr. Lewis Blevins on issues of relevance to pituitary disease.
Announcing our latest book: Prolactinomas
We are very pleased to announce our latest book on Prolactinomas. This is the 6th book in a series that includes tomes on Cushing’s, Hypopituitarism, Vasopressin Deficiency (formerly Diabetes Insipidus), Pituitary Adenomas, and Pituitary Disorders. The Prolactinomas book is available here and in all major book retailers.
Shaping the future of acromegaly care: Insights from the updated consensus guidelines
How should clinicians define disease control, select therapy, and personalize treatment for people living with acromegaly? A new three-part podcast series from The Pituitary Society explores these questions through the lens of the updated international consensus recommendations on therapeutic outcomes in acromegaly (Melmed S et al. Nat Rev Endocrinol 2025;21:718–37).
Worth noting:
Crinetics Pharmaceuticals, launches a new resource, Everyday Advocacy, with leading patient groups. Read more
From Debiopharm, read about Oxtend™ 3 clinical trial for acromegaly for a long term (3-month) octreotide treatment. More information here.
From Camurus more information on a new treatment option for acromegaly. Read more here
From Crinetics Pharmaceuticals, FDA approves Crinetics PALSONIFY™ for adults with acromegaly . Read more
Recordati announces FDA approval of ISTURISA® new indication in the U.S. to treat endogenous hypercortisolemia in patients with Cushing’s syndrome,- Learn more here
New support site from Chiesi; Rethink acromegaly
Chiesi relaunches a patient-facing website for Mycapssa.

Content for physicians and healthcare professionals.
Join a drug trial. Find out how. Here’s a partial list of studies.

Latest trends and a roundup of health and wellness news
The Podcast
Knowledge and information are critical tools to affect early diagnosis in pituitary disease. Join Dr. Lewis Blevins and Jorge D. Faccinetti cofounders, as they navigate the wonders and complexities of pituitary conditions.
Live Talk on Demand
At ENDO 2026, Dr. Richard Auchus of the University of Michigan shares his perspectives on the connection between type 2 diabetes and hard-to-control hypertension and high cortisol in Corcept Therapeutics’ landmark studies. The interview covers two related studies investigating how often “common” diseases—difficult-to-control diabetes and hypertension are actually being driven by undiagnosed adrenal dysfunction, particularly mild, clinically significant cortisol excess from adrenal adenomas.
Our live talk sessions of the pituitary and adrenal podcasts continue with this extremely informational conversation on hypothalamic obesity. If you are interested in learning more about his devastating disorder, please listen to Dr. Blevins as he shares his insights and extensive expertise on its causes, new treatments, and latest developments.



















